Results 181 to 190 of about 14,917 (240)

Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome. [PDF]

Mol Med
Nikolopoulos T, Bochalis E, Chatzilygeroudi T, Chondrou V, Dereki I, Athanasopoulou K, Zafeiropoulos J, Bourikas K, Patrinos GP, Symeonidis A, Sgourou A.   +10 more
europepmc   +1 more source

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. [PDF]

Leukemia
Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M.   +21 more
europepmc   +1 more source

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports. [PDF]

Front Oncol
Xiao Y, Yang K, Huang Q, Wei C, Wei M, Geng Z, Wu H, Zhou T, Yin X, Zhou Y.   +9 more
europepmc   +1 more source

Safety and infection risk factors in elderly acute myeloid leukemia patients undergoing induction therapy with venetoclax combined with hypomethylating agents. [PDF]

Am J Cancer Res
Zhu W, Zhu L, Hu X, Chen E, Xue L, Wang X, Zhu X, Zheng C, Tong J.   +8 more
europepmc   +1 more source

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents. [PDF]

Leukemia
Reuvekamp T, Ngai LL, den Hartog D, Carbaat-Ham J, Fayed MMHE, Scholten WJ, Mocking TR, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Breems D, van Lammeren-Venema D, Boersma R, Ossenkoppele GJ, van de Loosdrecht AA, Bachas C, Huls G, de Leeuw DC, Cloos J.   +20 more
europepmc   +1 more source

Efficacy and safety of hypomethylating agents in the treatment of AML/MDS patients relapsed post allogenetic hematopoietic stem cell transplantation. [PDF]

Front Oncol
Wang Y, Wang Q, Ren H, Dong Y, Wang Q, Liang Z, Yin Y, Liu W, Xu W, Han N, Li Y.   +10 more
europepmc   +1 more source

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. [PDF]

Cancer Med
Jin D, He J, Chen H, Wu W, Han X, Le J, Shu W, Yang Q, Pei S, Cai Z, He D.   +10 more
europepmc   +1 more source

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia. [PDF]

Blood Neoplasia
Madarang E, Lykon J, Zhao W, Sekeres MA, Bradley T, Chandhok NS, Taylor J, Venugopal S, Koru-Sengul T, Iyer SG, Gilbert JS, Miller RM, Nanni J, Zacheo I, Mattei A, Al Ali N, Kishtagari A, Marconi G, Sallman DA, Pollyea DA, Savona MR, Papayannidis C, Komrokji R, Watts J.   +23 more
europepmc   +1 more source

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients. [PDF]

Cancers (Basel)
Wang L, Gao H, Fu Q, Jiang Q, Jiang H, Wang Y, Xu L, Zhang X, Huang X, Tang F.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Hypomethylating Agents in Lymphoma

Current Treatment Options in Oncology, 2020
Epigenetic mutations are frequent and pathogenic in select subtypes of lymphoma, and agents modulating DNA and histone methylation-such as inhibitors of DNMT and EZH2, respectively-have demonstrated promise in treating these diseases. In particular, lymphomas derived from the germinal center-GC-DLBCL, FL, and AITL-are all characterized by epigenetic ...
Jacob C, Cogan, Yuxuan, Liu, Jennifer E, Amengual   +2 more
openaire   +2 more sources